So far, SII has made 5 crore doses of the Oxford University-AstraZeneca vaccine.
India will be the first priority for the delivery of the AstraZeneca-Oxford vaccine, Pune-based drugmaker said.
Serum Institute of India plans to make up to 10 crore doses of coronavirus vaccine each month, starting next year, said chief executive officer Adar Poonawalla. Pune-based drugmaker partnered with global pharma giant AstraZeneca to produce COVID-19 vaccine by University of Oxford for low-and-middle income countries. Dubbed as Covishield, the COVID-19 vaccine is currently in the Phase III clinical trial in India.
In an interview with The Associated Press, Poonawalla revealed that the pharma major is increasing its production capacity by the end of 2021 to over 250 crore doses a year to cope with future disease outbreaks. Poonawalla's company now has an annual capacity of 150 crore doses.
So far, the company has made 5 crore doses of the Oxford University-AstraZeneca vaccine. It has already applied for emergency use authorisation of the vaccine in India. India's drugs regulator said this week it had sought more data to make a decision on emergency authorisation for AstraZeneca's COVID-19 vaccine candidate.
“It’ll still take two months (after it is licensed) before large volumes roll out," CEO said.
Covishield is highly effective vaccine against novel coronavirus, Poonawalla said earlier. AstraZeneca and Oxford University earlier said that their drug had proved on average 70% effective at stopping the virus after trying it on 23,000 people. It uses a weakened version of a chimpanzee common coldvirus that encodes instructions for making proteins from the novel coronavirus to generate an immune response and prevent infection.
India will be the first priority for the delivery of the AstraZeneca-Oxford vaccine, the world's largest vaccine manufacturer by volume earlier mentioned. "The COVID-19 vaccine will be distributed initially in India, then we will look at the COVAX countries which are mainly in Africa. Our priority is India & COVAX countries," Poonawalla said.
The world's largest vaccine producer will also manufacture another formulation developed by Novavax Inc. Organizations such the GAVI vaccine group and the Bill & Melinda Gates Foundation are backing both candidates for large-scale distribution around the globe.
SII has secured funding from GAVI and the Gates Foundation to deliver up to 20 crore doses of both vaccines for India and other low-and middle-income countries. Under this agreement, the 10 crore doses of coronavirus vaccine will be priced at a maximum of $3 each.
Covishield is logistically feasible for distribution in the country's both urban and rural parts as it can be stored at two to eight degrees celsius.
Source - LiveMint
Adar Poonawalla, CEO, Serum Institute of India, receives the award for the Outstanding Business Leader of the Year
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.